Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Investors' Reports
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, October 2, 2013 /PRNewswire/ --
Today, Investors' Reports announced new research reports highlighting Celgene Corporation (NASDAQ: CELG), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Nektar Therapeutics (NASDAQ: NKTR), and Zalicus Inc. (NASDAQ: ZLCS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Celgene Corporation Research Report
On September 26, 2013, Celgene Corporation's subsidiary, Celgene International Sarl (Celgene International) announced that its will present the latest research findings on apremilast, an oral small-molecule selective inhibitor of phosphodiesterase 4 (PDE4), at the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting, to be held from October 25 to October 31, 2013 in San Diego. The Company informed that the data to be presented include the long-term results from two Phase III investigational trials, evaluating the treatment with apremilast for patients with psoriatic arthritis (PALACE 2), as well as in patients with psoriatic arthritis with skin involvement (PALACE 3). Further, Celgene International stated that the results from BCT-0001, a Phase II trial, evaluating apremilast in patients with Behcet's Disease with active oral ulcers will also be presented. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-29/CELG]
Biogen Idec Inc. Research Report
On September 24, 2013, Biogen Idec Inc. (Biogen Idec) announced that it has been named into the Dow Jones Sustainability World Index (DJSI World). The Company stated that the recognition makes Biogen Idec the first and only US-based biotech sector firm to be included in the list. The Company also informed that it has been named to the DJSI North America for the fourth consecutive year. Further, the Company stated that it has bagged the top Carbon Disclosure Score for the biotech sector in Carbon Disclosure Project's (CDP) Annual Investor Survey. The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-29/BIIB]
Amgen, Inc. Research Report
On September 28, 2013, Amgen, Inc. (Amgen) announced the results from the Phase 3 ASPECCT ('763) trial, which compared Vectibix (panitumumab) to Erbitux (cetuximab) for the treatment of wild-type KRAS metastatic colorectal cancer in patients who have not responded to chemotherapy. According to the Company, the study has met its primary endpoint, demonstrating that panitumumab was non-inferior to cetuximab for overall survival. Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen said, "ASPECCT was a well-conducted and robust Phase 3 trial involving nearly 1,000 patients globally with metastatic colorectal cancer, Colorectal cancer is a devastating disease and these results provide physicians with important new information about the role Vectibix can play as they evaluate treatment options." The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-29/AMGN]
Nektar Therapeutics Research Report
On September 26, 2013, Nektar Therapeutics (Nektar) reported the preliminary topline results from a Phase 2 study of NKTR-181 for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis of the knee. According to the Company, only 9 (3%) out of the 295 patients under study, were unable to achieve meaningful pain relief with NKTR-181, while 53 (18%) patients discontinued treatment during the titration period because of adverse events, while a total of 213 patients achieved an average 40% reduction in pain and entered the randomized phase of the study. "We were very pleased that this drug clearly performs as an effective analgesic with only 3% of the patients who received NKTR-181 unable to titrate to meaningful pain relief," said Howard W. Robin, President and CEO of Nektar. "We are carefully evaluating the lack of post-randomization rebound in the placebo arm in order to design the optimal pivotal trials for this drug. Based upon the data from this trial, it is clear that NKTR-181 provides pain relief on par with existing opioids while achieving a very favorable safety profile that differentiates it from standard opioids." The Full Research Report on Nektar Therapeutics - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-29/NKTR]
Zalicus Inc. Research Report
On September 27, 2013, Zalicus Inc. (Zalicus) announced that Z160, the Company's first-in-class, oral, state-dependent, selective N-type calcium channel modulator in development for chronic neuropathic pain, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia. "The FDA's designation of Z160 as having orphan drug status is an important milestone for Zalicus as we continue the clinical development work required for potential FDA approval of Z160," commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. Zalicus also informed that it had completed patient enrollment in two Phase 2 clinical studies of Z160 for chronic neuropathic pain indications including postherpetic neuralgia and lumbosacral radiculopathy on September 3, 2013.The Company added that the top-line results of both studies are expected in Q4 2013.The Full Research Report on Zalicus Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-29/ZLCS]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.